Biocomposites Launches geneX®ds. Extending the Reach of Injectable Bone Grafts

STAFFORDSHIRE, England--(BUSINESS WIRE)--Biocomposites, the pioneers in synthetic bone graft materials have launched geneX ds, a dual syringe mixing and minimally invasive delivery system containing geneX, the unique resorbable bone graft material with a negative surface charge.

“geneX ds incorporates everything I need in a bone void filler and is an adjunct to osseous unions. It is easy to mix, quick setting and radio dense. The geneX ds delivery system allows me to precisely apply the material directly to the surgical site.”

The powder and liquid components of geneX are provided pre-packed in separate syringes. The syringes connect together and allow a faster, simpler and cleaner way for mixing geneX. The resulting setting paste can then be delivered through an 8cm dispenser (included). geneX ds is ideal for difficult-to-reach surgical sites or minimally invasive procedures.

geneX is a synthetic bone graft material with a unique bi-phasic composition manufactured through a proprietary process ZPC^® (Zeta Potential Control) that confers the product with a reproducible negative surface charge. This property stimulates bone cell activity, accelerating bone formation and fusion by harnessing key proteins and directing osteoblast adhesion and proliferation for rapid osteogenesis. geneX is fully resorbable and is completely replaced by bone. geneX overcomes the surgeon’s reliance on donor tissue presenting both a cost saving and a reduction in the risks associated with its use.

Commenting on geneX ds, Dr Chris Gauland, Surgeon at the Eastern Carolina Foot and Ankle Specialists, North Carolina, USA said “geneX ds incorporates everything I need in a bone void filler and is an adjunct to osseous unions. It is easy to mix, quick setting and radio dense. The geneX ds delivery system allows me to precisely apply the material directly to the surgical site.”

Biocomposites’ Managing Director Stephen Bratt added “Expanding clinical evidence supporting the efficacy of ZPC technology in trauma has prompted surgeons’ requests for a geneX delivery system for complex cases. geneX ds addresses the surgeons’ needs for an easy-to-use mixing and delivery kit that will present geneX to a much wider surgeon and patient base.

geneX ds is FDA cleared and CE marked. Available now in 2.5cc.

geneX^®, ZPC^® and Biocomposites^® The Next Regeneration^® are registered trademarks of Biocomposites Ltd.

About the company:

Biocomposites is a privately held, leading developer, manufacturer and distributor of synthetic, tissue regeneration products. Since 1997, the company has developed a broad range of products that addresses the clinical and economic needs of medical specialties in orthopaedics and dentistry. Research, manufacturing, sales and marketing are directed from the company's headquarters in Keele, Staffordshire, UK. Biocomposites also has two regional companies, based in Shanghai, P.R.China and Wilmington, North Carolina, USA.